Abbott Point of Care Canada Limited Warning Letter Details

Summary

Abbott Point of Care Canada Limited, a manufacturer of medical devices, received a warning letter from the FDA's Center for Devices and Radiological Health on November 8, 2022, regarding an adulterated device associated with an Investigational Device Exemption (IDE) or Premarket Approval Application (PMA). Based on the available metadata alone, the letter appears to address concerns about device adulteration in the context of premarket regulatory pathways, though the specific nature of the adulteration and detailed violations are not evident from this limited information. Further review of the complete warning letter would be necessary to determine the full scope of compliance issues and required corrective actions.